Bugworks

Linked-in

BWC0977

IV + Oral step down small molecule agent for treating critical care infections

Phase 1

Phase 2

GYROX-2

Oral small molecule agent for treating community infections

Lead optimization

Phase 1

Coverage:

  • Critical priority pathogens including carbapenem resistant Enterobacteriaceae, Acinetobacter baumannii & Pseudomonas aeruginosa
  • High priority pathogens including Enterococcus faecium, Staphylococcus aureus, Campylobacter sp., Streptococcus pneumoniae
  • Bio-threat pathogens including Bacillus anthracis, Yersinia pestis, Francisella tularensis, Burkholderia mallei, Burkholderia pseudomallei

VIROX-1

IV + Oral small molecule agents for treating ssRNA infections

Lead generation

Phase 1

Coverage:

  • Corona viruses: SARS-CoV-2
  • Flavi viruses: West Nile, Dengue, Zika, Hepatitis C

DARE-1

Small molecule oral immuno-oncologic agents for treating multiple cancers

Lead optimization

Phase 1

Coverage:
  • Adenosine pathway Implied in CRC, NSCLC, TNBC, PANCREAS, PROSTATE, RCC, HNSCC
  • No FDA approved small molecule drug yet
  • Available immuno-oncology drugs are biologics presenting with huge cost and toxicity liabilities
  • Has a potential for combination with approved immune checkpoint drugs, cytotoxics and targeted therapies

Partners

Partner-CTA
to top